Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between protein S and complement C4b-binding protein (C4BP). Affinity studies using chimeras containing

R H van de Poel1, J C Meijers, B N Bouma

  • 1Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands. r.h.l.vandepoel@med.uu.nl

The Journal of Biological Chemistry
|May 18, 1999
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of thrombin activatable fibrinolysis inhibitor (TAFI).

Journal of thrombosis and haemostasis : JTH·2018
Same author

PO-28 - Protein C levels are associated with mortality in patients with advanced cancer.

Thrombosis research·2016
Same author

Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in hemophiliacs with inhibitors.

Thrombosis research·2010
Same author

Unraveling the mystery of von Willebrand factor.

Journal of thrombosis and haemostasis : JTH·2006
Same author

Discovery of thrombin activatable fibrinolysis inhibitor (TAFI).

Journal of thrombosis and haemostasis : JTH·2006
Same author

Effects of high plasma lipoprotein (a) levels on tissue factor pathway inhibitor and the protein C pathway.

Journal of thrombosis and haemostasis : JTH·2005

Human C4b-binding protein (C4BP) regulates the complement system and protein C pathway. Research shows C4BP beta-chain SCR-2 specifically contributes to binding anticoagulant protein S, impacting its function.

Area of Science:

  • Immunology
  • Biochemistry

Background:

  • Human C4b-binding protein (C4BP) is a key regulator of the complement system.
  • C4BP modulates the anticoagulant protein C pathway by binding protein S, reducing its cofactor activity for activated protein C.
  • The protein S binding site on C4BP beta-chain was previously localized to SCR-1.

Purpose of the Study:

  • To further delineate the specific domains of the C4BP beta-chain involved in protein S binding.
  • To elucidate the role of individual short consensus repeats (SCRs) in the interaction between C4BP and protein S.

Main Methods:

  • Construction of chimeric proteins fusing different C4BP beta-chain SCRs (SCR-1, SCR-2, SCR-3, SCR-1+2, SCR-1+3, SCR-2+3) to tissue-type plasminogen activator.
  • Binding assays to quantify the affinity of protein S for the C4BP beta-chain chimeras.

Related Experiment Videos

  • Functional assays measuring the cofactor activity of protein S in the presence of C4BP constructs.

    • Main Results:

    • Chimeras containing SCR-1 and SCR-2 (SCR-1+2) exhibited a 5-fold higher affinity for protein S compared to SCR-1 alone or SCR-1+3.
    • Binding of protein S to constructs containing SCR-1 reduced its cofactor activity, with SCR-1+2 showing more potent inhibition.
    • SCR-2 demonstrated a specific contribution to protein S binding, as SCR-3 did not enhance the interaction with SCR-1.

    Conclusions:

    • The beta-chain SCR-2 of C4BP plays a specific and significant role in the interaction with protein S.
    • This finding refines our understanding of C4BP's regulatory mechanism within the complement and protein C pathways.